ArticleAdvanced healthcare materials2026
Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
A carrier-free co-assembled nanoplatform, designated as IR@PF-M NPs, was developed to enhance photothermal-immunotherapy against triple-negative breast cancer (TNBC) by reprogramming methionine metabolism. The nanoplatform was constructed through the self-assembly of the methionine adenosyltransferase 2A (MAT2A) inhibitor PF9366 with the near-infrared (NIR)-absorbing dye IR808, followed by surface modification with DSPE-PEG2000-Met. This formulation exhibited dual targeting capabilities, enabling tumor accumulation via the enhanced permeability and retention effect and selective uptake by tumor cells through overexpressed methionine transporters, which together enhanced intratumoral accumulation and photothermal efficiency. Upon NIR irradiation, IR808 generated potent photothermal effects with intratumoral temperature beyond 50°C that induced immunogenic cell death (ICD) and transformed the tumor microenvironment into an immune-activated ("hot") state. Simultaneously, PF9366 disrupted methionine metabolism, further amplifying ICD and suppressing TNBC progression and metastasis. By integrating photothermal therapy with metabolic intervention, IR@PF-M NPs demonstrated superior antitumor efficacy and immunomodulatory activity, offering a promising therapeutic strategy for TNBC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.